Cell kinetics and cell cycle regulation in lymphomas

Journal of Clinical Pathology

Volumn 55, Issue 9, 2002, Pages 648-655

  Leoncini, L ^a   Lazzi, S ^a   Bellan, C ^a   Tosi, P ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CELL CYCLE; CELL GROWTH; CELL KINETICS; LYMPHOMA CELL; MAMMAL CELL; MITOSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW;

APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; HUMANS; LYMPHOMA, NON-HODGKIN; MITOSIS;

EID: 0036724323     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.55.9.648     Document Type: Review

References (106)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group
2. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997
3. Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody
4. Proliferating cell nuclear antigen (PCNA) immunolocalizaton in paraffin section: An index of cell proliferation with evidence of deregulated expression in some neoplasms
5. Mitotic activity and survival in advanced non-Hodgkin's lymphoma of unfavourable histology
6. 2+M phase fraction (flow cytometric analysis) and prognosis
7. Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
8. Proliferation indices in malignant lymphomas
9. How many mutations are required for tumorigenesis? Implications from human cancer data
10. Landscaping the cancer terrain
11. La cinetica cellulare per una classificazione bilogica dei linfomi
12. Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma
13. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression
14. The regulation of E2F by pRb family-proteins
15. Turnover of cyclin E by the ubiquitin-proteosome pathway is regulated by cdk2 binding and cyclin phosphorylation
16. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E
17. Cell cycle control of DNA replication
18. 1-phase progression
19. WAF1 CIP1 is induced in p53-mediated G1 arrest and apoptosis
20. Regulation of the G2/M transition by p53
21. Overexpression of PRAD1 in a mantle zone lymphoma patient with a t(11;12)(q13;q11) translocation
22. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity
23. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor
24. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity
25. Transcriptional and post-transcriptional mechanisms induce cydin-D1 over-expression in B-chronic lymphoproliferative disorders
26. Deletion and loss of expression of p16INK4a and p21 Waf1 genes are associated with aggressive variants of mantle cell lymphoma
27. Involvement of a human endogenous retroviral sequence (THE-7) in a t(7;14)(q21;q32) chromosomal translocation associated with a B-cell chronic lymphocytic leukemia
28. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations
29. Mammalian G1 cyclins
30. Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma
31. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: Prognostic significance of E2F-1 and p16INK4A
32. Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma
33. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas
34. Gene involved in the 3q27 translocation associated with B-cell lymphoma, BCL5, encodes a Krupel-like zinc-finger protein
35. The BCL-6 proto-oncogene controls germinal-centre formation and the Th2-type inflammation
36. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci
37. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: Independent prognostic value of p27Kip1
38. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. P/27KIP1-cyclin D3 colocalization in tumor cells
39. Loss of p16/INK4 protein expression in non-Hodgkin's lymphomas is a finding associated with tumoral progression. Inactivation of the CDKN2 gene is more frequently due to the novo methylation
40. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene
41. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies
42. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
43. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alteration in p53, p16, and p27
44. Molecular heterogeneity of B-lineage diffuse large cell lymphoma
45. The pathogenesis of Burkitt's lymphoma
46. cMyc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points
47. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27
48. Cip1
49. Point mutations in the c-MYC transactivation domain are common in Burkitt's lymphoma and mouse plasmacytoma
50. Mutations in the coding region of e-myc occur frequently in acquired immunodeficiency syndrome associated lymphomas
51. Sequence curiosity in v-myc oncogene
52. Interaction of e-myc with the pRb-related protein p107 results in inhibition of c-myc mediated transactivation
53. Binding and suppression of the c-myc transcriptional activation domain by p107
54. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases
55. Genetic alterations disrupting the nuclear localization of the retinoblastoma related gene RB2/p130 in human cell lines and primary tumors
56. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes
57. Cellular proliferation and genetic events involved in the genesis of Burkitt lymphoma (BL) in immune compromised patients
58. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation b of the c-myc transactivation domain
59. Expression af p34cdc2 and cyclins A and B compared to other proliferative features of non-Hodgkin's lymphomas: A multivariate cluster analysis
60. Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features
61. Cell cycle regulators p27 and pRb in lymphomas: Correlation with histology and proliferative activity
62. Retinoblastoma-related p107 and pRb2/p130 proteins in malignant lymphomas: Distinct mechanisms of cell growth control
63. Sequential dephosphorylation of p34cdk2 on Thr-14 and Tyr-15 at the prophase/metaphase transition
64. Intracellular localization of cyclin B1 during the cell cycle in glioma cells
65. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation
66. Identification of BIME as a subunit of the anaphase-promoting complex
67. Cell-cycle control and its watchman
68. Growth patterns of diffuse non-Hodgkin's lymphomas estimated from mitotic and apoptotic indices
69. Abortive mitosis and nuclear DNA fragmentation in CD30+ large cells of Hodgkin's disease
70. Growth vs. DNA strand breaks in Hodgkin's disease: Impaired proliferative ability of Hodgkin and Reed-Sternberg cells
71. Proliferative activity in Reed-Sternberg cells
72. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines
73. Cellular kinetic differences between Hodgkin's and anaplastic large cell lymphomas: Relation to the expression of p34ckc2 and cyclin B-1
74. Expression of the ALK protein by anaplastic large-cell lymphomas correlates with high proliferative activity
75. Molecular characterization of ALK a receptor tyrosine kinase expressed specifically in the nervous system
76. ALK, the chromosome 2 gene locus altered by t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase
77. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM in non-Hodgkin's lymphoma
78. Oncogenic activation of tyrosine kinases
79. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity
80. ALK+ CD30+ lymphomas: A distinct molecular genetic subtype of non-Hodgkin's lymphoma
81. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat Ia fibroblasts
82. Assessing apoptosis: A critical survey
83. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas
84. Apoptotic index from fine needle aspiration cytology as a criterion to predict histologic grade of non-Hodgkin's lymphoma
85. Low versus high cell turnover in diffusely growing non-Hodgkin's lymphomas
86. Apoptosis and cancer. Strategies for integrating programmed cell death
87. Bcl-2 and ICE family of apoptotic regulators: Making a connection
88. Regulators of cell death
89. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death
90. New members of the Bcl-2 family and their protein partners
91. Presence of the bcl-2 protein and apoptosis in non-Hodgkin lymphomas with diffuse growth pattern
92. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray
93. FADD/MORTI is a common mediator of CD95 Fas/AOP-1 and tumor necrosis factor receptor induced apoptosis
94. Distinct molecular mechanisms of Fas resistance in murine B lymphoma cells
95. B-cell receptor and Fas-mediated signals for life and death
96. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells
97. Constitutive NF-kappa B maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells
98. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells
99. The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18) (q21,q21) associated with mucosa-associated lymphoid tissue lymphoma
100. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
101. Regulation of cell growth and death by Epstein-Barr virus
102. Cellular kinetic and phenotypic heterogeneity in and among Burkitt's and Burkitt-like lymphomas
103. Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma
104. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line
105. The RB2/p130 gene: The latest weapon in the war against lung cancer?